Literature DB >> 7332737

Peritoneal absorption of the antibacterial and antiendotoxin taurolin in peritonitis.

B I Knight, G G Skellern, M K Browne, R W Pfirrmann.   

Abstract

1 Taurolin metabolite plasma concentrations were measured in two groups of patient undergoing abdominal surgery, one group with peritonitis and the other without peritonitis, each group receiving taurolin by intraperitoneal instillation. 2 There was no significant difference in the area under the curves, for the two groups, for one of the metabolites. This would suggest that the absorption of taurolin was not modified in inflammatory conditions such as bacterial peritonitis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7332737      PMCID: PMC1401955          DOI: 10.1111/j.1365-2125.1981.tb01292.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  The in vitro and in vivo activity of taurolin against anaerobic pathogenic organisms.

Authors:  M K Browne; G B Leslie; R W Pfirrman; H Brodhage
Journal:  Surg Gynecol Obstet       Date:  1977-12

2.  Intraperitoneal irrigation with povidone-iodine solution for the prevention of intra-abdominal abscesses in the bacterially contaminated abdomen.

Authors:  W F Sindelar; G R Mason
Journal:  Surg Gynecol Obstet       Date:  1979-03

3.  The anti-endotoxin activity of Taurolin in experimental animals.

Authors:  R W Pfirrmann; G B Leslie
Journal:  J Appl Bacteriol       Date:  1979-02

4.  Continuing peritoneal lavage in high-risk peritonitis.

Authors:  M Stephen; J Loewenthal
Journal:  Surgery       Date:  1979-06       Impact factor: 3.982

5.  [Experimental substantiation of the efficacy of peritoneal novocaine block by the Vishnevskiĭ method in peritonitis].

Authors:  N N Fomin
Journal:  Eksp Khir Anesteziol       Date:  1968 May-Jun

6.  Taurolin, a new chemotherapeutic agent.

Authors:  M K Browne; G B Leslie; R W Pfirrmann
Journal:  J Appl Bacteriol       Date:  1976-12

7.  The relationship between structure and activity of taurolin.

Authors:  E Myers; M C Allwood; M J Gidley; J K Sanders
Journal:  J Appl Bacteriol       Date:  1980-02

8.  The characterisation and quantitation by high-performance liquid chromatography of the metabolites of taurolin.

Authors:  B I Knight; G G Skellern; M K Browne; R W Pfirrmann
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

9.  C controlled trial of taurolin in established bacterial peritonitis.

Authors:  M K Browne; M MacKenzie; P J Doyle
Journal:  Surg Gynecol Obstet       Date:  1978-05
  9 in total
  4 in total

1.  Influence of intraperitoneal and systemic application of taurolidine and taurolidine/heparin during laparoscopy on intraperitoneal and subcutaneous tumour growth in rats.

Authors:  C Braumann; J Ordemann; P Wildbrett; C A Jacobi
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats.

Authors:  Chris Braumann; Marco Schoenbeck; Charalambos Menenakos; Maik Kilian; Christoph A Jacobi
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines.

Authors:  Denise K Walters; Roman Muff; Bettina Langsam; Philipp Gruber; Walter Born; Bruno Fuchs
Journal:  Invest New Drugs       Date:  2007-04-26       Impact factor: 3.850

4.  Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy.

Authors:  Chris Braumann; Jürgen Ordemann; Maik Kilian; Frank A Wenger; Christoph A Jacobi
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.